Atazanavir/cobicistat explained
| Type: | combo |
| Component1: | Atazanavir |
| Class1: | HIV protease inhibitor |
| Component2: | Cobicistat |
| Class2: | Cytochrome P450 (CYP3A) inhibitor |
| Tradename: | Evotaz |
| Dailymedid: | Atazanavir_and_cobicistat |
| Atc Prefix: | J05 |
| Atc Suffix: | AR15 |
| Legal Uk: | POM |
| Legal Uk Comment: | [1] |
| Legal Us: | Rx-only |
| Legal Us Comment: | [2] |
| Legal Eu: | Rx-only |
| Legal Eu Comment: | [3] |
| Cas Number: | 2446322-19-4 |
| Kegg: | D10753 |
Atazanavir/cobicistat, sold under the brand name Evotaz, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains atazanavir and cobicistat.[4] Atazanavir is an HIV protease inhibitor and cobicistat is an inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A family.
Atazanavir/cobicistat was approved by the Food and Drug Administration (FDA) for medical use in United States in January 2015.[5] [6] It was approved for medical use in the European Union in July 2015.
Medical uses
Atazanavir/cobicistat is indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1 infection in people weighing at least 35kg (77lb).
External links
Notes and References
- Web site: Evotaz 300 mg/150 mg film-coated tablets - Summary of Product Characteristics (SmPC) . (emc) . 9 July 2021.
- Web site: Evotaz- atazanavir and cobicistat tablet . DailyMed . 25 May 2021.
- Web site: Evotaz EPAR . European Medicines Agency (EMA) . 17 September 2018 . 25 May 2021.
- Crutchley RD, Guduru RC, Cheng AM . Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection . HIV/AIDS: Research and Palliative Care. 8 . 47–65 . 2016 . 27022304 . 4790521 . 10.2147/HIV.S99063 . free .
- U.S. Food and Drug Administration Approves Bristol-Myers Squibb's Evotaz (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults . Bristol-Myers Squibb . 2018-06-28 . 2020-08-08 . https://web.archive.org/web/20200808213616/https://news.bms.com/press-release/financial-news/us-food-and-drug-administration-approves-bristol-myers-squibbs-evotaz-a . dead .
- Web site: Evotaz (atazanavir and cobicistat) Tablet . U.S. Food and Drug Administration (FDA) . 15 April 2016 . 25 May 2021 . Web site: Summary Report.
